Medicenna Therapeutics Corp. (MDNAF)
OTCMKTS · Delayed Price · Currency is USD
0.5620
-0.0204 (-3.50%)
Feb 11, 2026, 3:26 PM EST
Medicenna Therapeutics Employees
Medicenna Therapeutics had 18 employees as of March 31, 2025. The number of employees increased by 2 or 12.50% compared to the previous year.
Employees
18
Change (1Y)
2
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$551,013
Market Cap
46.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 18 | 2 | 12.50% |
| Mar 31, 2024 | 16 | 0 | - |
| Mar 31, 2023 | 16 | -2 | -11.11% |
| Mar 31, 2022 | 18 | 5 | 38.46% |
| Mar 31, 2021 | 13 | 6 | 85.71% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Oncotelic Therapeutics | 26 |
| Nuo Therapeutics | 9 |
| Harvard Apparatus Regenerative Technology | 8 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
| Finch Therapeutics Group | 1 |
Medicenna Therapeutics News
- 4 weeks ago - Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook - GlobeNewsWire
- 2 months ago - Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy Transcript - Seeking Alpha
- 2 months ago - Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy - Slideshow - Seeking Alpha
- 2 months ago - Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors - GlobeNewsWire
- 2 months ago - Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data - GlobeNewsWire
- 3 months ago - Medicenna Therapeutics GAAP EPS of -C$0.06 - Seeking Alpha
- 4 months ago - Updated MDNA11 Clinical Data from the ABILITY-1 Study to be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025 - GlobeNewsWire
- 4 months ago - Medicenna Therapeutics Announces Participation in Upcoming Conferences - GlobeNewsWire